Table 1 Patients’ characteristics
n = 105 | |
|---|---|
Age (years) | 65 (37–79)a |
Gender (male/female), n (%) | 71 (68%) / 34 (32%) |
Performance status 0, n (%) | 38 (36%) |
1, n (%) | 63 (60%) |
2, n (%) | 4 (4%) |
Line of treatment 1st line, n (%) | 56 (53%) |
2nd line or later, n (%) | 49 (47%) |
Presence of lung disease, n (%) | 9 (9%) |
Presence of lung metastasis, n (%) | 12 (11%) |
History of pulmonary surgery, n (%) | 0 (0%) |
History of lung irradiation, n (%) | 3 (3%) |
Smoker, n (%) | 55 (52%) |
Presence of heart disease, n (%) | 20 (19%) |
GnP number of doses (time) | 8 (2–63)a |
GnP administration period (days) | 101 (7–931)a |
GEM cumulative dosage (mg) | 12,050 (2400-88,200+)a |
nabPTX cumulative dosage (mg) | 1520 (360–7364+)a |
ILD frequency, n (%) | 10 (9.5%) |
Period from initiation of treatment to onset (days) | 79 (34–202)a |
Cumulative number of doses of GnP (time) | 8 (3–28)a |